The management of vulval disorders in Genitourinary Medicine (GUM) clinics requires targeted approaches due to the wide range of conditions affecting the vulva. Vulval diseases encompass various aetiologies, including dermatoses, pain syndromes, and pre-malignant conditions, necessitating specialized care often involving multidisciplinary collaboration.
Purpose
This guideline aims to provide evidence-based recommendations for the diagnosis and management of specific vulval conditions that may present in GUM clinics. The focus is on conditions commonly managed by Genitourinary Physicians, either independently or in partnership with other specialists, depending on available local expertise. Additionally, guidance on onward referral is included to ensure optimal patient care.
Study Sample
The guideline primarily addresses the management of individuals aged 16 years and older presenting to GUM clinics with non-infective vulval conditions.
Data Collection
Recommendations within this guideline are derived from a review of existing literature, clinical expertise, and consensus among specialists. Emphasis is placed on diagnostic tests and treatment regimens tailored to the following conditions: Lichen sclerosus, Lichen planus, Eczema, Lichen simplex, Psoriasis, Vulval high-grade squamous intraepithelial lesions (previously vulval intraepithelial neoplasia), Vulval pain syndromes, and Non-sexually acquired acute genital ulceration (Ulcer of Lipschütz).
Conclusions
This guideline offers practical recommendations for the effective management of specific vulval disorders in GUM settings. It is not intended to be a comprehensive review of all vulval diseases but rather a focused resource to assist clinicians in providing high-quality, patient-centred care. Onward referral pathways are also outlined to support collaborative and multidisciplinary management of complex cases.
van der MeijdenWIBoffaMJTer HarmselWA, et al.2016 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol2017; 31(6): 925–941. DOI: 10.1111/jdv.14096.
British Society for the Study of Vulval Disease. Patient information leaflets. Available at: https://www.bssvd.org/leaflets.asp (accessed 02 November 2022).
HalonenPJakobssonMHeikinheimoO, et al.Incidence of lichen sclerosus and subsequent causes of death: a nationwide Finnish register study. BJOG2020; 127: 814–819.
8.
LeibovitzAKaplunVVSaposhnicovN, et al.Vulvovaginal examinations in elderly nursing home women residents. Arch Gerontol Geriatr2000; 31(1): 1–4.
9.
LewisFMTatnallFMVelangiSS, et al.British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol2018; 178(4): 839–853.
10.
OyamaNChanINeillSM, et al.Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet2003; 362: 118–123.
11.
Meyrick-ThomasRHRidleyCMMcGibbonDH, et al.Lichen sclerosus et atrophicus and autoimmunity-a study of 350 women. Br J Dermatol1988; 118: 41–46.
12.
TranDATanXMacriCJ, et al.Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci2019; 15(7): 1429–1439.
13.
WallaceHJ. Lichen sclerosus et atrophicus. Trans St John’s Hosp Dermatol Soc1971; 57: 9–30.
14.
LeeABradfordJFischerG. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol2015; 151: 1061–1067.
15.
RegauerSReichO. Early vulvar lichen sclerosus: a histological challenge. Histopathology2005; 47: 340–347.
16.
VirgiliAMinghettiSBorghiA, et al.Long-term maintenance therapy for vulvar lichen sclerosus: the results of a randomized study comparing topical vitamin E with an emollient. Eur J Dermatol2013; 23: 189–194.
17.
ChiCCKirtschigGBaldoM, et al.Topical interventions for genital lichen sclerosus (review). Cochrane Libr2011; 7: CD008240.
18.
BorghiACorazzaMMinghettiS, et al.Continuous vs. tapering application of the potent topical corticosteroid mometasone furoate in the treatment of vulvar lichen sclerosus: results of a randomized trial. Br J Dermatol2015; 173(6): 1381–1386.
19.
VirgiliAMinghettiSBorghiA, et al.Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol2013; 168: 1316–1324.
20.
VirgiliABorghiAToniG, et al.First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol2014; 171: 388–396.
21.
HenggeURKrauseWHofmannH, et al.Multi-centre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol2006; 155: 1021–1028.
22.
NissiREriksenHRisteliJ, et al.Pimecrolimus cream 1% in the treatment of lichen sclerosus. Gynecol Obstet Invest2006; 63: 151–154.
23.
FunaroDLovettALerouxN, et al.A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol2014; 71: 84–91.
24.
EdeyKBissonDKennedyC. Topical tacrolimus in the management of lichen sclerosus. Br J Obstet Gynaecol2006; 113: 1482–1483.
25.
FischerGBradfordJ. Topical immunosuppressants, genital lichen sclerosus and the risk of squamous cell carcinoma: a case report. J Reprod Med2007; 52: 329–331.
26.
BousemaMTRomppanenUGeigerJM, et al.Acitretin in the treatment of severe lichen sclerosus et atrophicus of the vulva: a double-blind, placebo controlled study. J Am Acad Dermatol1994; 30: 225–231.
27.
BeattiePEDaweRSFergusonJ, et al.UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol2006; 31: 343–347.
28.
TerrasSGambichlerTMoritzRKC, et al.UV-A1 phototherapy vs clobetasol propionate, 0.05%, in the treatment of vulvar lichen sclerosus: a randomized clinical trial. JAMA Dermatol2014; 150: 621–627.
29.
TaskerFKirbyLGrindlayD, et al.Laser therapy for genital lichen sclerosus: a systematic review of the current evidence base. Skin Health and Disease2021; 1(3): e52.
30.
EshtiaghiPSadownikLA. Fact or fiction? Adipose-derived stem cells and platelet-rich plasma for the treatment of vulvar lichen sclerosus. J Low Genit Tract Dis2019; 23(1): 65–70.
31.
TrokoudesDLewisFM. Lichen sclerosus - the course during pregnancy and effect on delivery. J Eur Acad Dermatol Venereol2019; 33(12): e466–e468.
32.
AbramovYElchalalUAbramovD, et al.Surgical treatment of vulvar lichen sclerosus: a review. Obstet Gynecol Surv1996; 51: 193–199.
33.
CooperSMDeanDAllenJ, et al.Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. Clin Exp Dermatol2005; 30: 551–556.
DayTMooreSBohlTG, et al.Comorbid vulvar lichen planus and lichen sclerosus. J Low Genit Tract Dis2017; 21(3): 204–208.
36.
LewisFMShahMHarringtonCI. Vulval involvement in lichen planus: a study of 37 women. Br J Dermatol1996; 135: 89–91.
37.
GenadryRProvostTT. Severe vulvar scarring in patients with erosive lichen planus: a report of 4 cases. J Reprod Med2006; 51: 67–72.
38.
SetterfieldJFNeillSShirlawPJ, et al.The vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele. J Am Acad Dermatol2006; 55(1): 98–113.
39.
CooperSMWojnarowskaF. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol2006; 142: 289–294.
40.
DayTOttonGJaabackK, et al.Is vulvovaginal lichen planus associated with squamous cell carcinoma?J Low Genit Tract Dis2018; 22(2): 159–165.
41.
SimpsonRCThomasKSLeightonP, et al.Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. Br J Dermatol2013; 169(2): 337–343.
42.
ChengHOakleyARowanD, et al.Diagnostic criteria in 72 women with erosive vulvovaginal lichen planus. Australas J Dermatol2016; 57(4): 284–287.
43.
CooperSMAliIBaldoM, et al.The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol2008; 144(11): 1432–1435.
KirtschigGVan Der MeulenAJIon LipanJW, et al.Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. Br J Dermatol2002; 147(3): 625–626.
Lonsdale-EcclesAAVelangiS. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol2005; 153(2): 390–394.
48.
BradfordJFischerG. Management of vulvovaginal lichen planus: a new approach. J Low Genit Tract Dis2013; 17(1): 28–32.
49.
Nylander LundqvistEWahlinYBHoferPA. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen ruber. Acta Derm Venereol2002; 82(1): 63–64.
50.
JangNFischerG. Treatment of erosive vulvovaginal lichen planus with methotrexate. Australas J Dermatol2008; 49(4): 216–219.
51.
ClineACuellar-BarbozaAJorizzoJL, et al.Methotrexate for the treatment of recalcitrant erosive lichen planus of the vulva. JAMA Dermatol2020; 156(2): 215–217.
52.
VermeerHABRashidHEsajasMD, et al.The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina. Br J Dermatol2021; 185(1): 201–203.
53.
WeeJSShirlawPJChallacombeSJ, et al.Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol2012; 167: 36–43.
54.
DeenKMcMenimanE. Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature. J Dermatol2015; 42(3): 311–314.
55.
BoyceAEMarshmanGMillsRA. Erosive mucosal lichen planus and secondary epiphora responding to systemic cyclosporin A treatment. Australas J Dermatol2009; 50(3): 190–193.
56.
ReboraAParodiAMarialdoG. Basiliximab is effective for erosive lichen planus. Arch Dermatol2002; 138: 1100–1111.
57.
TétuPMonfortJBBarbaudA, et al.Failure of rituximab in refractory erosive lichen planus. Br J Dermatol2018; 179(4): 980–981.
58.
HelgesenALWarloeTPrippAH, et al.Vulvovaginal photodynamic therapy vs. topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. Br J Dermatol2015; 173(5): 1156–1162.
59.
RajkumarSLewisFNathR. The importance of topical steroids after adhesiolysis in erosive lichen planus and graft versus host disease. J Obstet Gynaecol2019; 39: 82–85.
60.
FischerGSpurrettBFischerA. The chronically symptomatic vulva: aetiology and management. Br J Obstet Gynaecol1995; 102(10): 773–779.
61.
FischerGO. The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Aust J Dermatol1996; 37: 12–18.
62.
BallSBWojnarowskaF. Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus. Semin Cutan Med Surg1998; 17(3): 182–188.
63.
CheungSTGachJELewisFM. A retrospective study of the referral patterns to a vulval clinic: highlighting educational needs in this subspecialty. J Obstet Gynaecol2006; 26(5): 435–437.
64.
StewartEWojnarowskaF. The vulval clinic – how is it used?J Eur Acad Dermatol Venereol1995; 5.
65.
DrislaneCIrvineAD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol2020; 124(1): 36–43.
66.
CroneAMStewartEJWojnarowskaF, et al.Aetiological factors in vulvar dermatitis. J Eur Acad Dermatol Venereol2000; 14: 181–186.
67.
UtaşSFerahbaşAYildizS. Patients with vulval pruritus: patch test results. Contact Dermatitis2008; 58(5): 296–298.
68.
HaverhoekEReidCGordonL, et al.Prospective study of patch testing in patients with vulval pruritus. Australas J Dermatol2008; 49(2): 80–85.
69.
Al-NiaimiFFeltonSWilliamsJ. Patch testing for vulval symptoms: our experience with 282 patients. Clin Exp Dermatol2014; 39(4): 439–442.
NardelliADegreefHGoossensA. Contact allergic reactions of the vulva: a 14-year review. Dermatitis2004; 15(3): 131–136.
72.
O'GormanSMTorgersonRR. Allergic contact dermatitis of the vulva. Dermatitis2013; 24(2): 64–72.
73.
GoldsmithPCRycroftRJWhiteIR, et al.Contact sensitivity in women with anogenital dermatoses. Contact Dermatitis1997; 36(3): 174–175.
74.
ChengHSFernández-PeñasP. Allergic contact dermatitis of the anogenital region in men and women. J Low Genit Tract Dis2020; 24(2): 221–224.
75.
FelminghamCDavenportRPalmerA, et al.Vulval allergic contact dermatitis: medicaments are a common cause. Australas J Dermatol2020; 61(4): 388–390.
76.
LewisFMShahMGawkrodgerDJ. Contact sensitivity in pruritus vulvae: patch test results and clinical outcome. Am J Contact Dermat1997; 8(3): 137–140.
77.
BrenanJADennersteinGJSfameniSF, et al.Evaluation of patch testing in patients with chronic vulvar symptoms. Australas J Dermatol1996; 37(1): 40–43.
78.
VermaatHSmienkFRustemeyerT, et al.Anogenital allergic contact dermatitis, the role of spices and flavour allergy. Contact Dermatitis2008; 59(4): 233–237.
79.
VermaatHvan MeursTRustemeyerT, et al.Vulval allergic contact dermatitis due to peppermint oil in herbal tea. Contact Dermatitis2008; 58(6): 364–365.
LynchPJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. Dermatol Ther2004; 17: 8–19.
82.
JohnstonGAExtonLSMohd MustapaMF, et al.British association of dermatologists’ guidelines for the management of contact dermatitis 2017. Br J Dermatol2017; 176(2): 317–329. DOI: 10.1111/bjd.15239.
83.
van ZuurenEJFedorowiczZChristensenR, et al.Emollients and moisturisers for eczema. Cochrane Database Syst Rev2017; 2(2): CD012119. DOI: 10.1002/14651858.CD012119.pub2.
84.
WollenbergABarbarotSBieberT, et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol2018; 32(5): 657–682. DOI: 10.1111/jdv.14891.
85.
GoldsteinATThaçiDLugerT. Topical calcineurin inhibitors for the treatment of vulvar dermatoses. Eur J Obstet Gynecol Reprod Biol2009; 146(1): 22–29. DOI: 10.1016/j.ejogrb.2009.05.026.
86.
BlackRJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin Exp Dermatol2005; 30: 91–92.
87.
MerolaJFBleakmanAPGottliebAB, et al.The static physician’s global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol2017; 16: 793–799.
88.
RyanC. Genital psoriasis: the failure of dermatologists to identify genital involvement. Br J Dermatol2019; 180: 460–461.
89.
KellyARyanC. Genital psoriasis: impact on quality of life and treatment options. Am J Clin Dermatol2019; 20: 639–646.
90.
AlpalhãoMBorges-CostaJFilipeP. Psoriasis in HIV infection: an update. Int J STD AIDS2019; 30: 596–604.
91.
MeeuwisKAde HulluJAMassugerLF, et al.Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol2011; 91: 5–11.
92.
HongJJMoscaMLHadelerEK, et al.Genital and inverse/intertriginous psoriasis: an updated review of therapies and recommendations for practical management. Dermatol Ther2021; 11: 833–844.
93.
GuentherLLyndeCPoulinY. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg2019; 23(4_suppl): 27S–34S.
94.
BurlandoMHerzumACarmiscianoL, et al.Biological therapy in genital psoriasis in women. Dermatol Ther2020; 33: e13110.
95.
LarsabalMLySSbidianE, et al.GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol2019; 180(3): 647–656.
96.
BornsteinJBogliattoFHaefnerHK, et al.The 2015 international society for the study of vulvovaginal disease (ISSVD) terminology of vulvar squamous intraepithelial lesions. Low Genit Tract Dis2016; 20(1): 11–14.
97.
ThuijsNBvan BeurdenMBrugginkAH, et al.Vulvar intraepithelial neoplasia: incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer2021; 148(1): 90–98.
AlbuquerqueAGodfreyMALCappelloC, et al.Multizonal anogenital neoplasia in women: a cohort analysis. BMC Cancer2021; 21(1): 232.
100.
DayTMarzolAPaganoR, et al.Clinicopathologic diagnosis of differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J Low Genit Tract Dis2020; 24(4): 392–398.
101.
HellerDSDayTAllbrittonJI, et al.Diagnostic criteria for differentiated vulvar intraepithelial neoplasia and vulvar aberrant maturation. J Low Genit Tract Dis2021; 25(1): 57–70.
102.
Gonzalez-BosquetEMazaricoELorenteN, et al.Risk factors to develop multicentric lesions of the lower genital tract. Eur J Gynaecol Oncol2017; 38(1): 10–13.
103.
SatmaryWHolschneiderCHBrunetteLL, et al.Vulvar intraepithelial neoplasia: risk factors for recurrence. Gynecol Oncol2018; 148(1): 126–131.
104.
FehrMKBaumannMMuellerM, et al.Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. J Gynecol Oncol2013; 24(3): 236–241.
105.
NageleEReichOGreimelE, et al.Sexual activity, psychosexual distress, and fear of progression in women with human papillomavirus-related premalignant genital lesions. J Sex Med2016; 13(2): 253–259.
106.
HoangLNParkKJSoslowRA, et al.Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology2016; 48(4): 291–302.
PepasLKaushikSNordinA, et al.Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev2015; 2015(8): CD007924.
109.
LawrieTANordinAChakrabartiM, et al.Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev2016; 2016(1): CD011837.
110.
GreenNAdedipeTDmytryshynJ, et al.Management of vulvar cancer precursors: a survey of the international society for the study of vulvovaginal disease. J Low Genit Tract Dis2020; 24(4): 387–391.
111.
von GruenigenVEGibbonsHEGibbinsK, et al.Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol2007; 109(4): 942–947.
112.
SterlingJCSmithNALooWJ, et al.Randomized, doubleblind, placebo-controlled trial for treatment of high grade vulval intraepithelial neoplasia with imiquimod. JEADV2005; 19(Suppl 2): 22.
113.
HurtCNJonesSMaddenTA, et al.Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multicentre, randomised, phase II trial (RT3VIN). BJOG2018; 125(9): 1171–1177.
114.
TrutnovskyGReichOJouraEA, et al.337 Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. Baseline results of a randomized clinical trial. Int J Gynecol Cancer2020; 30: A108.
115.
JouraEALeodolterSHernandez-AvilaM, et al.Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet2007; 369: 1693–1702.
116.
BryanSBarbaraCThomasJ, et al.HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review. BMC Wom Health2019; 19(1): 3.
117.
GhelardiAMarraiRBoganiG, et al.Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease. Vaccines (Basel)2021; 9(2): 83.
118.
LipschützB. Über eine eigenartige Geschwulstform des weiblichen Genitales (Ulcus vulave acutum). Arch Dermatol Syph1913; 114: 363–395.
119.
SadoghiBStaryGWolfP, et al.Ulcus vulvae acutum Lipschutz: a systematic literature review and a diagnostic and therapeutic algorithm. J Eur Acad Dermatol Venereol2020; 34(7): 1432–1439.
120.
VismaraSALavaSAGKottanattuL, et al.Lipschutz’s acute vulvar ulcer: a systematic review. Eur J Pediatr2020; 179(10): 1559–1567.
121.
FarhiDWendlingJMolinariE, et al.Non-sexually related acute genital ulcers in 13 pubertal girls: a clinical and microbiological study. Arch Dermatol2009; 145(1): 38–45. DOI: 10.1001/archdermatol.2008.519.
122.
ChristlJAlanizVIAppiahL, et al.Vulvar aphthous ulcer in an adolescent with COVID-19. J Pediatr Adolesc Gynecol2021; 34(3): 418–420.
123.
LautenschlagerSKempMChristensenJJ, et al.2017 European guideline for the management of chancroid. Int J STD AIDS2017; 28(4): 324–329. DOI: 10.1177/0956462416687913.
124.
BornsteinJGoldsteinAStockdaleC, et al.2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. J Low Genit Tract Dis2016; 20: 126–130.
125.
ReedBDHarlowSDSenA, et al.Prevalence and demographic characteristics of vulvodynia in a population-based sample. Am J Obstet Gynecol2012; 206: 170.e1–170.e1709. DOI: 10.1016/j.ajog.2011.08.012.
126.
ThorntonADrummondC. Current concepts in vulvodynia with a focus on pathogenesis and pain mechanisms. Australas J Dermatol2016; 57: 253–263.
127.
WesselmannUBonhamAFosterD. Vulvodynia: current state of the biological science. Pain2014; 155: 1696–1701.
128.
FarmerMATalorAMBaileyAL, et al.Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. Sci Trans Med2011; 3: 101ra92.
129.
LeusinkPvan de PaschSTeunissenD, et al.The relationship between vulvovaginal candidiasis and provoked vulvodynia: a systematic review. J Sex Med2018; 15(9): 1310–1321.
130.
FalsettaMLFosterDCBonhamAD, et al.A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation. BJOG2016; 124: 210–218.
131.
GardellaBPorruDNappiRE, et al.Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case-control study. J Sex Med2011; 8: 1726–1734.
132.
ReedBDHarlowSDSenA, et al.Relationship between vulvodynia and chronic comorbid pain conditions. Obstet Gynecol2012; 120: 145–151.
133.
GoldsteinATBelkinZRKrapfJM, et al.Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. J Sex Med2014; 11: 2764–2771.
134.
HeddiniUBohm-StarkeNGrönbladhA, et al.Serotonin receptor gene (5HT-2A) polymorphism is associated with provoked vestibulodynia and comorbid symptoms of pain. J Sex Med2014; 11: 3064–3071.
135.
HarlowBLVitonisAFStewartEG. Influence of oral contraceptive use on the risk of adult-onset vulvodynia. J Reprod Med2008; 53: 102–110.
136.
GerberSBongiovanniAMLedgerWJ, et al.Defective regulation of the proinflammatory immune response in women with vulvar vestibulitis syndrome. Am J Obstet Gynecol2002; 186: 696–700.
137.
ReissingEDBrownCLordMJ, et al.Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome. J Psychosom Obstet Gynecol2005; 26: 107–113.
138.
MorinMBergeronSKhaliféS, et al.Morphometry of the pelvic floor muscles in women with and without provoked vestibulodynia using 4D ultrasound. J Sex Med2014; 11: 776–785.
139.
PukallCFStrigoIABinikYM, et al.Neural correlates of painful genital touch in women with vulvar vestibulitis syndrome. Pain2005; 115: 118–127.
140.
Bohm-StarkeNHilligesMBrodda-JansenG, et al.Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain2001; 94: 177–183.
141.
KhandkerMBradySSVitonisAF, et al.The influence of depression and anxiety on risk of adult onset vulvodynia. J Womens Health (Larchmt)2011; 20: 1445–1451.
142.
DesrochersGBergeronSLandryT, et al.Do psychosexual factors play a role in the etiology of provoked vestibulodynia? A critical review. J Sex Marital Ther2008; 34: 198–226.
143.
PetrosPBornsteinJ. Re: vulvar vestibulitis may be a referred pain arising from laxity in the uterosacral ligaments: a hypothesis based on three prospective case reports. Aust N Z J Obstet Gynaecol2004; 44: 484–485.
144.
BecoJ. Interest of retro-anal levator plate myorrhaphy in selected cases of descending perineum syndrome with positive anti-sagging test. BMC Surg2008; 8: 13.
Patient information leaflet. Vulval pain society. Available at: https://vulvalpainsociety.org/ (accessed 02 November 2022).
150.
DavisSBergeronSBinikY, et al.Women with provoked vestibulodynia experience clinically significant reductions in pain regardless of treatment: results from a 2-year follow-up study. J Sex Med2013; 10: 3080–3087.
151.
NunnsDMandalDByrneM, et al.Guidelines for the management of vulvodynia. Br J Dermatol2010; 162: 1180–1185.
152.
ShallcrossRDicksonJMNunnsD, et al.Women’s subjective experiences of living with vulvodynia: a systematic review and meta-ethnography. Arch Sex Behav2018; 47: 577–595. DOI: 10.1007/s10508-017-1026-1.
153.
SpoelstraSKDijkstraJRvan DrielMF, et al.Longterm results of an individualized, multifaceted, and multidisciplinary therapeutic approach to provoked vestibulodynia. J Sex Med2011; 8: 489–496.
154.
Miranda Varella PereiraGSoriano MarcolinoMSilveira Nogueira ReisZ, et al.A systematic review of drug treatment of vulvodynia: evidence of a strong placebo effect. BJOG2018; 125: 1216–1224. DOI: 10.1111/1471-0528.15223.
155.
FosterDCKotokMBHuangLS, et al.Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol2010; 116(3): 583–593. DOI: 10.1097/AOG.0b013e3181e9e0ab.
156.
Gentilcore-SaulnierEMcLeanLGoldfingerC, et al.Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. J Sex Med2010; 7(2 Pt 2): 1003–1022.
157.
MurinaFBernorioRPalmiottoR. The use of amielle vaginal trainers as adjuvant in the treatment of vestibulodynia: an observational multicentric study. Medscape J Med2008; 10: 23.
158.
KarpBTandonHVigilD, et al.Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders. Int Urogynecol J2019; 30: 1071–1081. DOI: 10.1007/s00192-018-3831-z.
159.
DesrochersGBergeronSKhalifeS, et al.Provoked vestibulodynia: psychological predictors of topical and cognitive-behavioral treatment outcome. Behav Res Ther2010; 48: 106–115.
160.
TommolaPUnkila-KallioLPaavonenJ. Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Acta Obstet Gynecol Scand2011; 90: 1225–1231.
161.
EvaLJNarainSOrakwueCO, et al.Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. J Reprod Med2008; 53: 435–440.
162.
PetersKGirdlerBCarricoD, et al.Painful bladder syndrome/interstitial cystitis and vulvodynia: a clinical correlation. Int Urogynecol J2008; 19: 665–669.
163.
ReedBDCaronAMGorenfloDW, et al.Treatment of vulvodynia with tricyclic antidepressants: efficacy and associated factors. J Low Genit Tract Dis2006; 10: 245–251.
164.
Pérez-LópezFRBueno-NotivolJHernandezAV, et al.Systematic review and meta-analysis of the effects of treatment modalities for vestibulodynia in women. Eur J Contracept Reprod Health Care2019; 24(5): 337–346. DOI: 10.1080/13625187.2019.1643835.
165.
HarrisGHorowitzBBorgidaA. Evaluation of gabapentin in the treatment of generalized vulvodynia, unprovoked. J Reprod Med2007; 52(2): 103–106.
166.
JeromeL. Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. Pain Res Manag2007; 12: 212–214.
167.
MurinaFBiancoVRadiciG, et al.Transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomised controlled trial. BJOG2008; 115: 1165–1170.
168.
MashebRMKernsRDLozanoC, et al.A randomized clinical trial for women with vulvodynia: cognitive-behavioral therapy vs supportive psychotherapy. Pain2009; 141: 31–40.
169.
PowellJWojnarowskaF. Acupuncture for vulvodynia. J R Soc Med1999; 92: 579–581.
